Pacific Biosciences of California, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christian O. Henry
- Full Time Employees
- 575
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1305 O’Brien Drive Menlo Park CA United States of America 94025
- IPO Date
- Oct 27, 2010
- CIK
- 0001299130
- Website
- pacb.com
- Similar Companies
- Business
- Pacific Biosciences of California, Inc. (PacBio) designs, develops, and manufactures advanced sequencing solutions to resolve genetically complex problems in life sciences research and clinical applications; its core offerings include long-read HiFi sequencing systems such as the Revio production-scale platform delivering up to 120 Gb per SMRT Cell with SPRQ-Nx chemistry, the Vega benchtop system providing 60 Gb per SMRT Cell, and legacy Sequel II and Sequel IIe instruments; short-read sequencing via the Onso system powered by sequencing by binding (SBB) chemistry achieving 90% Q40 accuracy; consumables encompassing SMRTbell library preparation kits, reagent kits including ligase, buffers, exonucleases, flow cells, clustering, and sequencing reagents; and software solutions like SMRT Link for analysis, Paraphase variant caller, and applications for whole genome sequencing, targeted sequencing, epigenetics, RNA isoform sequencing, and PureTarget assays for repeat expansions and carrier screening. The company serves academic and governmental research institutions, genome centers, public health labs, hospitals, clinical research institutes, contract research organizations, pharmaceutical firms, and agricultural companies across the Americas, Europe, Middle East, Africa, Asia Pacific including China and Japan, and other regions through direct sales and distribution partners. Incorporated in 2000 and headquartered at 1305 O'Brien Drive in Menlo Park, California, PacBio operates in the biotechnology sector focusing on human genetics, plant and animal sciences, infectious disease, oncology, and emerging multiomic applications. Recent developments include the launch of SPRQ-Nx chemistry in 2025 targeting up to 40% reduction in HiFi genome sequencing costs to under $300 per genome at scale with beta testing on Revio starting November 2025 and commercial availability in 2026; expanded PureTarget portfolio with updated repeat expansion and new carrier screening panels plus 96-plex automation kits; distribution agreement with Haorui Gene in 2025 to promote platforms including Vega in China's clinical labs for blood typing genomics and precision medicine; Class III medical device approval in China for Sequel II CNDx system via partner Berry Genomics in November 2025; partnership with Epicycle for FiberSeq chromatin analysis integration; selection of Revio for the U.S. National Institute on Aging's Long Life Family Study sequencing up to 7,800 genomes and epigenomes, and the Korean Pangenome Reference Project for over 1,000 genomes; and publication of HiFi Solves EMEA Consortium preprint demonstrating 100% detection of pathogenic variants in complex regions.
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why
Here's Why You Should Add PacBio Stock to Your Portfolio Now
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
PacBio Expands HiFi Sequencing Reach With New SPRQ-Nx Technology
PacBio SPRQ-Nx Chemistry Now Shipping Worldwide, Enabling Sub-$300 HiFi Genomes for Large Scale Projects and AI-Enhanced Sequencing
PacBio to Participate in the Jefferies Global Healthcare Conference
PACB & Blank Bio Partner to Advance RNA Foundation Models in Oncology
Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology
HiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy Loss
Pacific Biosciences of California Q1 Earnings Call Highlights
PACB Q1 Earnings Beat, Revenues Miss Estimates, Gross Margin Down
Pacific Biosciences of California, Inc. (PACB) Q1 2026 Earnings Call Transcript
Pacific Biosciences of California (PACB) Reports Q1 Loss, Lags Revenue Estimates
PacBio Announces First Quarter 2026 Financial Results
PacBio Pre-Q1 Analysis: Time to Buy, Hold or Sell the Stock Now?
Critical Review: Autonomix Medical (NASDAQ:AMIX) and Pacific Biosciences of California (NASDAQ:PACB)
Pacific Biosciences of California (PACB) Stock Declines While Market Improves: Some Information for Investors
PacBio & Lucid Genomics Partner to Boost Data Analysis, Stock Up
PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing
PacBio Stock Up on New FFPE Workflow Boosting Cancer Sequencing